AzTrials
AzTrials

Adrenal Insufficiency NeonatalNCT02956707

Impact of Pre-operative Steroids on Adrenal Insufficiency

An observational study of Adrenal Insufficiency Neonatal, run by University of Alabama at Birmingham at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Little is known regarding the incidence and clinical impact of AI in neonates during the acute postoperative period following separation from CPB. In a randomized control pilot study performed by the UAB CVICU research team, prophylactic post-CPB hydrocortisone infusions improved some postoperative outcomes… Read more about this study

Who is it for?
Ages 1 day to 60 days
Conditions the study is for
Adrenal Insufficiency Neonatal
What is being tested?
No pre-operative steroids
Type of treatment
Injection or infusion
How many people
50 participants
Where
1 siteUnited States
Study dates
Jul 2016to 12 Jan 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 60 days
  • All sexes
  • No healthy volunteers
  • Child

Study population: Neonates less than 30 days old undergoing cardiac surgery with cardiopulmonary bypass who do not receive pre-operative steroid administration as part of their standard of care medical management.

Inclusion Criteria:40 consecutive neonates (≤30 days of age) with complex congenital heart disease undergoing cardiac surgery with CPB who will not be given preoperative steroids.

  • Controls: 40 neonates with complex congenital heart disease undergoing cardiac surgery with CPB who received two doses of preoperative methylprednisolone (10mg/kg at eight hours and one hour prior to their operation). Data from this cohort has already been prospectively collected during the original pilot randomized control trial. Based on our clinical data over the past 8 years, the demographic and risk factors of the two cohorts will be very similar.

Exclusion Criteria: Neonates who do not require CPB during cardiac surgery or fail to separate from CPB in the operating room.

-

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233

Other trials in United States

About this study

Official title: Impact of Pre-operative Steroids on Adrenal Insufficiency and Clinical Outcomes After Neonatal Cardiac Surgery With Cardiopulmonary Bypass

Little is known regarding the incidence and clinical impact of AI in neonates during the acute postoperative period following separation from CPB. In a randomized control pilot study performed by the UAB CVICU research team, prophylactic post-CPB hydrocortisone infusions improved some postoperative outcomes, especially in those that acquired AI7. In an attempt to further explore post-CPB AI, a retrospective analysis of data from this study was performed. Of the 40 neonates included in the study, one-third (32.5%) developed AI following CPB (as determined by low-dose, 1 µg, cosyntropin stimulation test). Almost all of these subjects had normal response to cosyntropin stimulation pre-CPB. Subjects that developed AI demonstrated more hemodynamic instability, increased serum lactate and required more colloid resuscitation in the immediate post-CPB period in the operating room. Recent evidence has begun to highlight potential morbidity associated with perioperative steroid administration. Our cardiac surgery program is changing clinical practice and ceasing to give preoperative steroids to all patients (previously only neonatal CPB patients received preoperative methylprednisolone). With the possibility that preoperative steroid administration, and not CPB, primarily causes the high incidence of AI, it is prudent to further investigate the benefit and/or harm of perioperative steroid administration

Read the detailed description

Cardiopulmonary bypass (CPB) induces systemic inflammatory response syndrome (SIRS), which may contribute to postoperative morbidity. Neonates experience an exaggerated inflammatory response and may be at a higher risk for the deleterious effects of CPB. SIRS may disrupt the hypothalamic-pituitary-adrenal (HPA) axis leading to a relative adrenal insufficiency (AI) after neonatal CPB. There is some emerging evidence supporting an association of AI with morbidity in neonates after cardiac surgery. Postoperative steroids may offer hemodynamic benefits to neonates suffering from low cardiac output syndrome (LCOS) following CPB. Benefit of postoperative steroids is multifactorial including: suppression of inflammatory cytokines, direct actions on the heart and vascular smooth muscle, and treatment of AI in a subset of patients.

Little is known regarding the incidence and clinical impact of AI in neonates during the acute postoperative period following separation from CPB. In a randomized control pilot study performed by the UAB CVICU research team, prophylactic post-CPB hydrocortisone infusions improved some postoperative outcomes, especially in those that acquired AI. In an attempt to further explore post-CPB AI, a retrospective analysis of data from this study was performed. Of the 40 neonates included in the study, one-third (32.5%) developed AI following CPB (as determined by low-dose, 1 µg, cosyntropin stimulation test). Almost all of these subjects had normal response to cosyntropin stimulation pre-CPB. Subjects that developed AI demonstrated more hemodynamic instability, increased serum lactate and required more colloid resuscitation in the immediate post-CPB period in the operating room.

In this retrospective analysis by Crawford et al.8 ACTH levels were found to be significantly lower post-CPB compared to preoperative levels. This may be secondary to a blunted HPA axis caused by preoperative methylprednisolone (all patients received), which could result in transient, iatrogenic AI. Serum cytokines were not significantly different in patients exhibiting AI compared to those with a normal adrenal response indicating that increased inflammation was not primarily responsible for the development of AI. Higher methylprednisolone levels result in higher cortisol levels due to cross-reactivity of the assays; patients with higher baseline postoperative cortisol levels demonstrated a blunted response to cosyntropin suggesting that these patients may have higher blood concentrations of methylprednisolone and its metabolites, thereby leading to more inhibition of the HPA axis. Taken together, these two studies demonstrate that AI occurs at high frequency after neonatal CPB and that AI is associated with deleterious outcomes. While postoperative hydrocortisone improves outcomes in neonates with AI, the investigator cannot exclude preoperative methylprednisolone as a cause of iatrogenic AI. Other investigators have shown in children treated with dexamethasone prior to surgery, that higher measured levels of dexamethasone were associated with postoperative AI9.

The majority of congenital heart surgery centers utilize perioperative steroids in neonates undergoing cardiac surgery with the rationale that it modulates post-CPB SIRS and treats/prevents AI; studies have inconsistently demonstrated benefit of this approach. Additionally, recent evidence has begun to highlight potential morbidity associated with perioperative steroid administration. Our cardiac surgery program is changing clinical practice and ceasing to give preoperative steroids to all patients (previously only neonatal CPB patients received preoperative methylprednisolone). With the possibility that preoperative steroid administration, and not CPB, primarily causes the high incidence of AI, it is prudent to further investigate the benefit and/or harm of perioperative steroid administration.

With these facts in mind, the investigator designed this study to determine the impact of preoperative steroid administration on development of AI and other outcomes after neonatal cardiac surgery.

  1. Herein the investigator proposes to test the following HYPOTHESES and address these SPECIFIC AIMS:

HYPOTHESES: Preoperative steroid (methylprednisolone) administration is associated with development of iatrogenic AI; AI leads to increased postoperative morbidity. Preoperative steroids do not have important impact on other postoperative clinical outcomes.

SPECIFIC AIM# 1: Determine the incidence of AI (as diagnosed by 1µg cosyntropin stimulation testing) following CPB in neonates who do not receive preoperative steroids; compare to the previous cohort that received preoperative steroids.

SPECIFIC AIM# 2: Compare ACTH and cortisol levels between the two cohorts of neonates (those who do and those who do not receive preoperative steroids).

SPECIFIC AIM# 3: Compare secondary clinical outcomes including volume of crystalloid/colloid administered in the CVOR, hemodynamic parameters, laboratory values, vasoactive-inotrope score (VIS), duration of mechanical ventilation, fluid overload and mortality of the two cohorts of neonates.

Being tested
No pre-operative steroids
Keywords
neonates, cardiopulmonary bypass, adrenal insufficiency, congenital heart disease
Medical subject headings
Adrenal Insufficiency, Heart Defects, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No pre-operative steroidsOther

    Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.

Study groups in NCT02956707
Study groupRoleWhat they receive
No pre-operative steroidsThis is a prospectively enrolling group of 40 subjects. Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment. Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit.
Receives: Other: No pre-operative steroids
Pre-operative steroidsThis is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of AI in neonates who do not receive preoperative methylprednisolone

    Measured: 1 year

Secondary outcomes (15)
  1. Hemodynamic parameters-Heart rate

    hemodynamic parameters collected every 15 minutes post-CPB for 1.5 hours or until the end of the procedure-heart rate

    Measured: 1.5 hours post-CPB

  2. Hemodynamic parameters- Blood pressure

    hemodynamic parameters collected every 15 minutes post-CPB for 1.5 hours or until the end of the procedure systolic blood pressure

    Measured: 1.5 hours post-CPB

  3. Hemodynamic parameters- Central venous pressure

    hemodynamic parameters collected every 15 minutes post-CPB for 1.5 hours or until the end of the procedure central venous pressure

    Measured: 1.5 hours post-CPB

  4. Hemodynamic parameters- Flank Near infrared spectroscopy

    hemodynamic parameters collected every 15 minutes post-CPB for 1.5 hours or until the end of the procedure flank near infrared spectroscopy.

    Measured: 1.5 hours post-CPB

  5. Hemodynamic parameters- cerebral near infrared spectroscopy

    hemodynamic parameters collected every 15 minutes post-CPB for 1.5 hours or until the end of the procedure cerebral near infrared spectroscopy.

    Measured: 1.5 hours post-CPB

  6. Laboratory values- lactacte

    serum lactate

    Measured: 1 week post-CPB

  7. Laboratory values- Hematocrit

    hematocrit

    Measured: 1 week post-CPB

  8. Laboratory values- hemoglobin

    hemoglobin

    Measured: 1 week post-CPB

  9. Laboratory values- Mixed venous

    mixed venous oxygen saturation

    Measured: 1 week post-CPB

  10. Laboratory values- carbon dioxide

    veno-arterial carbon dioxide difference is the carbon dioxide from the venous blood gas minus the carbon dioxide from the arterial blood gas.

    Measured: 1 week post-CPB

  11. Laboratory values- oxygen content

    arterial and venous oxygen content is the saturation from the arterial blood gas and the saturation from the venous blood gas

    Measured: 1 week post-CPB

  12. Colloid/blood product volumes administered in the cardiovascular operating room

    volume in mililiters of crystalloids and colloids (albumin, fresh frozen plasma, packed red blood cells, and platelets) administered in the operating room

    Measured: intraoperative period

  13. Inotrope infusion doses

    incidence of low cardiac output syndrome based on inotropic support requirement in the post-operative period

    Measured: 48 hours post-CPB

  14. Inflammatory cytokines

    plasma will be collected and sent for inflammatory cytokine analysis at the following time points: pre-operative, 0 hour, 4 hour, 24 hour, and 48 hour post-cardiopulmonary bypass

    Measured: 48 hours post-CPB

  15. ACTH stimulation test

    ACTH testing will be performed preoperative, immediately post-CPB, and prior to CICU discharge. This testing includes the following:

    Baseline ACTH and cortisol levels, administration of cosyntropin, 30 minutes post-cosyntropin cortisol level

    Measured: 14 days post-CPB

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Nov 2016 (estimated)
  2. Study startJul 2016
  3. Primary completion12 Jan 2019
  4. Study completion12 Jan 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02956707
Sponsor's protocol ID
F160616001
Status last verified
Jan 2019
First submitted
14 Oct 2016
Last updated
15 Jan 2019
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No: On de-identified study data will be published

Questions about this trial

What is this clinical trial studying?

An observational study of Adrenal Insufficiency Neonatal, run by University of Alabama at Birmingham at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of AI in neonates who do not receive preoperative methylprednisolone (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in